Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aytu Biopharma Inc (NQ: AYTU )

2.050 -0.080 (-3.76%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 64,509
Open 2.120
Bid (Size) 2.050 (1)
Ask (Size) 2.350 (1)
Prev. Close 2.130
Today's Range 2.030 - 2.160
52wk Range 1.950 - 23.20
Shares Outstanding 3,573,262
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Aytu BioPharma's Return On Capital Employed Insights
 
Via Benzinga
Aytu BioPharma Reports Second Quarter of Fiscal Year 2023
Via ACCESSWIRE

Performance

YTD
-48.05%
-48.05%
1 Month
-30.27%
-30.27%
3 Month
-51.12%
-51.12%
6 Month
-46.67%
-46.67%
1 Year
-90.77%
-90.77%

More News

Read More
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023
Via ACCESSWIRE
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial Results
Via ACCESSWIRE
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023
Via ACCESSWIRE
Aytu BioPharma Regains Nasdaq Minimum Bid Price Compliance
Via ACCESSWIRE
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a Row
Via ACCESSWIRE
Aytu BioPharma Reports Record Quarterly Revenue and Positive Adjusted EBITDA in First Quarter of Fiscal Year 2023
Via ACCESSWIRE
Earnings Scheduled For February 14, 2023
Via Benzinga
Earnings Preview For Aytu BioPharma
Via Benzinga
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31
Via ACCESSWIRE
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD Patients
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Aytu BioPharma Announces 1-for-20 Reverse Stock Split
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Aytu BioPharma Announces Agreement with Avenue Venture Debt Fund to Extend Interest-Only Period of Company's Term Loan
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Muscle Maker And 2 Other Stocks Under $1 Insiders Are Aggressively Buying
Via Benzinga
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnect
Via ACCESSWIRE
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Via ACCESSWIRE
Aytu BioPharma Announces the Passing of Co-Founder and Board Member Michael Macaluso
Via ACCESSWIRE
Why Array Technologies Shares Are Trading Sharply Higher; Here Are 28 Stocks Moving Premarket
Via Benzinga
Aytu BioPharma to Report First Quarter Fiscal 2023 Financial Results on November 14, 2022
Via ACCESSWIRE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.